TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Ca...(International Group Institute JulesBorde...),Health

Date:5/12/2008

International Group, Institute Jules Bordet, Brussels, and investigator on Neo-ALTTO. "All too often clinicians and patients face the problem of disease recurrence, and women with high levels of HER2 protein are at a greater risk of this occurring. It is vital that early stage breast cancer is treated effectively from the outset with the right combination or sequence of therapies."

Neo-ALTTO is a three-arm, randomized, multi-center, open-label Phase III study of neoadjuvant TYKERB, neoadjuvant trastuzumab and a combination of neoadjuvant TYKERB and trastuzumab in women with HER2-positive primary breast cancer. After treatment for six weeks, the same targeted therapy will be repeated for 12 weeks with the addition of paclitaxel. Surgery will be performed on all patients, after which each patient will receive three courses of chemotherapy followed by the same targeted therapy for 34 weeks.

The primary objective of Neo-ALTTO is to evaluate and compare the rate of pathological complete response (or complete eradication of the tumor) at the time of surgery as well as understand the biological difference of the three treatment regimens using a neoadjuvant approach. Secondary objectives include measurements of safety and tolerability, tumor response rate, disease-free survival and overall survival. Target enrollment is 450 patients with 130 clinical trial centers participating across 26 different countries.

It is hoped that Neo-ALTTO will lead to the discovery of new molecular biomarkers that help to better identify the benefits of TYKERB or trastuzumab.

"GSK is proud to collaborate with such esteemed research groups as BIG and SOLTI for the study of TYKERB in this early breast cancer setting," said Paolo Paoletti, MD, Senior Vice President, Oncology Medicines Development Center of GSK. "This important global Phase III study, which has been enrolling within a year of the FDA approval of TYKERB, demonstrates the confidence that the oncolo
'/>"/>

SOURCE GlaxoSmithKline; Breast International Group; SpanishBreast Cancer Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
2. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
3. Hospital Launches Landmark Emergency Medicine Project
4. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
5. Viatronix V3D-Colon Utilized in Another Landmark Study
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
8. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
9. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
10. Gene Therapy Provides Vision to People who Were Nearly Blind
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein